• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio

    Frontage Bolsters Clinical Services Capabilities

    Sanofi Unveils EUROAPI as Name of New European API Company

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza

    Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center

    LSNE Expands Fill Finish and Lyophilization Ops
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Virtual Clinical Trials: The Future of Dermatology Studies

    Frontage Bolsters Clinical Services Capabilities

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics

    The Wasdell Group Earns ISO 13485 Certification
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Adare Pharma Solutions

    Reed-Lane

    Emergent BioSolutions

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Cytovance Biologics

    Emergent BioSolutions

    PCI Pharma Services

    Adare Pharma Solutions

    Syngene
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    Bristol-Myers Squibb

    ...

    Related CONTENT
    • Natoli Engineering Appoints Northeast Service Technician
    • Evotec, BMS Advance Targeted Protein Degradation Projects
    • Mogene
    • BMS to Acquire MyoKardia for $13.1B
    • Frontida BioPharm Launches Expansion Efforts
    07.01.10

    #9 - Bristol-Myers Squibb



    345 Park Ave.
    New York, NY 10154-0037
    Tel: (212) 546-4000
    Fax: (212) 546-4020
    www.bms.com

    Headcount 28,402  
    Year Established 1887  
    Pharma Revenues $18,808 +6%
    Total Revenues $18,808 +6%
    Net Income $5,602 +17%
    R&D Budget $3,647 +4%

    2009 Top Selling Drugs
    Drug Indication Sales (+/-%)
    Plavix platelet inhibitor $6,146 +10%
    Abilify schizophrenia $2,592 +20%
    Reyataz HIV/AIDS $1,401 +9%
    Avapro hypertension $1,283 -1%
    Sustiva HIV/AIDS $1,277 +11%
    Baraclude hepatitis B $734 +36%
    Erbitux colorectal cancer $683 -9%
    Orencia rheumatoid arthritis $602 +37%

    Account for 78% of total pharma sales, up from 75% in 2008.

     

    PROFILE



    Bristol-Myers Squibb continued its “next-generation biopharma” quest last year, spinning off its remaining non-pharma unit via limited IPO and pushing a slew of new potential blockbusters through the pipeline. Will they come up with enough new products to offset the loss of their biggest sellers? Not right away, and that’s the challenge facing new chief executive officer Lamberto Andreotti.
    The Lowe Down

    Let us now mark another year of an independent Bristol-Myers Squibb! If you printed out all the various rumors and scenarios about who they’d merge with or be bought by over the last ten years, you’d have one long (and excruciating) read. Others fall, though, while they keep going on.

    The anticoagulant market has been very good to them, what with all that Plavix money coming in. But in 2012 the flow will stop, if you’ll pardon the expression. Apixaban might well be ready to pick things up by then if things go well, giving the company a long stretch of staying afloat by sharing cardiovascular revenues with someone else.

    But there’s no room for pride in this industry, or at least not any more. Those revenues will certainly be enough to go around if the market forecasts are anywhere near right. You could ask Bayer about that, though, since they had similar dreams about their own Factor X compound, and those don’t look to be quite fulfilled. Several other companies could chime in with anticoagulant stories that didn’t work out they way they were supposed to, either. I wish BMS luck on this one, but they should also hope that their oncology and immune pipelines deliver something, just in case. —Derek Lowe

    Mr. Andreotti took over that role from James Cornelius in May 2010; the board elected to keep Mr. Cornelius in his role as chairman. Mr. Andreotti, 59, was previously president and chief operating officer, joining the company in 1998, so he’s seen some highs and lows at BMS. He has his work cut out for him, albeit not because of any mess left behind by his predecessor. BMS is simply facing the realities of being a mid-tier pharma company. It’s a tough role; your resources are constrained (relative to your big competitors), but you’re just as susceptible to The Patent Cliff as the big shots are. On top of that, you’re perennially seen as a takeover target. Some analysts believe that the company authorized a $3 billion stock buyback largely to whittle down its large cash on hand, making it a less attractive target.

    The company’s strategy remains to double-down on developing new drugs, both internal and licensed, and make strategic acquisitions. In this era of diversification, genericization, and geographic breadth, BMS is relying on R&D to save the day. That hasn’t worked out too well for pharma these last few years, but it could pay off for BMS if its new slate of drugs reaches the market. It’s a big “if.” A few Phase III failures, and we’re looking at another Top 10 company disappearing from the board.

    That’s because BMS’s biggest seller, Plavix, is expected to lose patent protection in the U.S. at the end of 2011. There’s already been some generic erosion for Plavix in Europe (which is more Sanofi’s worry than BMS’s), but U.S. sales have remained strong, up 13% in 2009 to $5.6 billion and 18% in 1Q10 to $1.5 billion. How is BMS going to make up the slack? They’ve already conceded that there’s no replacing Plavix. The company told investors and analysts in March of this year that income in 2013 will be between 9% and 13% lower than 2010’s projected levels, as the Plavix shortfall shakes out and Avapro sales slide. Abilify, the company’s second largest drug, is currently facing patent challenges from at least seven generic companies, but at press time is still protected until at least 2015.
    Outsourcing News

    In June 2010, BMS signed strategic, three-year clinical development agreements with ICON and PAREXEL. The companies will provide BMS with global support for clinical studies to accommodate its “robust pipeline and significant inlicensing activity,” according to BMS.

    ICON and PAREXEL “will complement [BMS’s] internal high-performing capabilities and capacity with high-quality clinical development services from partners who can drive efficiency and cost savings,” read the statement, which also noted that ICON has worked with BMS for 10 years.

    In July 2009, BMS bid approximately $2.3 billion to acquire Medarex, its development partner in ipilimumab, a melanoma biotherapeutic. The tender was completed in December. Medarex’s transgenic mouse antibody technology has been used in a number of marketed biologics — Simponi, Stelara, and Ilaris — providing BMS with a royalty stream to go along Medarex’s technology and its pipeline. BMS has high hopes for ipilimumab; the company recently released Phase III data showing that it’s the first drug that improves survival in patients with metastatic melanoma. The results look great; if they can mitigate the heavy-duty immune side-effects that beset some patients, they may have a blockbuster on their hands. (It’s also being tested against prostate and lung cancers.)

    After a 2008 setback in a venous thromboembolism trial, BMS’s apixaban did so well in its a new Phase III study that BMS and development partner Pfizer shut down the trial early. The trial’s independent data monitoring committee determined that apixaban bestowed a “clinically important reduction” in stroke and systemic embolism in atrial fibrillation patients. The trial involved 5,600 patients who were at risk but intolerant or unsuitable for warfarin therapy. BMS brought in Pfizer as its development partner in 2007.

    That was just around the same time BMS united with AZ to develop Onglyza, a treatment for type 2 diabetes. Onglyza was approved by the FDA in July 2009. It hasn’t set the world on fire, but it’s a DPP-4 inhibitor entering the post-Avandia diabetes market, and that means there’s plenty of caution among doctors. The companies are optimistic about its prospects, despite its lack of “overnight success.” Some analysts contend that “instant blockbusters” are a thing of the past (see Multaq, Effient, etc.), and that building a large franchise will take a lot more work in the current safety and reimbursement atmosphere.
    Acquisition News

    Target: Medarex

    Price: $2.3 billion

    Announced: July 2009

    What they said: “With its productive and proven antibody discovery capabilities, ability to generate interesting therapeutic programs and unique set of preclinical and clinical assets in development, Medarex represents what we’re looking for in terms of our String of Pearls strategy.” —James M. Cornelius, chairman and (then) CEO, BMS

    BMS and AZ are also in Phase III trials with dapagliflozin, another type 2 diabetes treatment that performed well with Metformin, the generic standard treatment, and recently filed an NDA for a combo of Onglyza and Metformin.

    Belatacept and brivanib comprise the other drugs that BMS hopes to launch by 2012 to put it in position for post-Plavix success (meaning, after the 2013 drop). Unfortunately, Belatacept faced a setback in May 2010 when the FDA sent BMS a CRL, asking for 12 more months of data from ongoing Phase III trials.

    Brivanib, a cancer treatment, is a bit more perplexing. As recently as March 2010, the company included it among the five new drugs it will launch by 2012. At press time, BMS was still recruiting patients for several Phase III trials for brivanib — in combination with Erbitux for colon cancer, and in a number of liver cancer scenarios — so I think a 2012 approval is a bit of a longshot.

    I have a soft spot in my heart for BMS. In the 10 years I’ve been compiling this report, they’ve really adopted the most naked make-or-break strategy I can recall.

    Previous profile: Eli Lilly & Co. // Next profile: Abbott Laboratories

     

    Return to Top Pharma Report homepage.
    Related Searches
    • contractpharma
    • Development Services
    • Outsourcing
    • Development
    Suggested For You
    Natoli Engineering Appoints Northeast Service Technician Natoli Engineering Appoints Northeast Service Technician
    Evotec, BMS Advance Targeted Protein Degradation Projects Evotec, BMS Advance Targeted Protein Degradation Projects
    Mogene Mogene
    BMS to Acquire MyoKardia for $13.1B BMS to Acquire MyoKardia for $13.1B
    Frontida BioPharm Launches Expansion Efforts Frontida BioPharm Launches Expansion Efforts
    Recro Gainesville Expands Mfg. Capabilities Recro Gainesville Expands Mfg. Capabilities
    Diverse Products And Technologies Delivered Diverse Products And Technologies Delivered
    PPD Expands Vaccine Development Lab PPD Expands Vaccine Development Lab
    UPM Celebrates 100-Years of Mfg. at Tennessee Site UPM Celebrates 100-Years of Mfg. at Tennessee Site
    BMS Names EVP, CSO BMS Names EVP, CSO
    CPhI North America Debuts in Philadelphia May 16 - 18 CPhI North America Debuts in Philadelphia May 16 - 18
    Innate Achieves $15M BMS Milestone Innate Achieves $15M BMS Milestone
    BMS, Janssen Enter Immuno-Oncology Alliance BMS, Janssen Enter Immuno-Oncology Alliance
    Portola Gets $50M from BMS, Pfizer for AndexXa Development Portola Gets $50M from BMS, Pfizer for AndexXa Development
    BMS Makes Leadership Changes BMS Makes Leadership Changes

    Related Top Companies Report

    • 25 CSL Behring

      25 CSL Behring

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 22 Astellas

      22 Astellas

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 21 Biogen

      21 Biogen

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20


    • 12 Amgen

      12 Amgen

      ...
      Tim Wright, Editor, Contract Pharma 07.20.20

    • 13 Gilead Sciences

      13 Gilead Sciences

      ...
      Kristin Brooks, Managing Editor 07.15.20

    • 10 Bristol-Myers Squibb

      10 Bristol-Myers Squibb

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.15.20


    • 03 Novartis

      03 Novartis

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 02 Roche

      02 Roche

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 09 Takeda

      09 Takeda

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20


    • 01 Pfizer, Inc.

      01 Pfizer, Inc.

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • The 2020 Top 25 Pharma and Biopharma Companies

      The 2020 Top 25 Pharma and Biopharma Companies

      Top 25 Pharma and Biopharma Companies (Based on 2019 Pharma/Biopharma Sales, in $U.S. Millions)
      Contract Pharma Staff 07.15.20

    • 08 GlaxoSmithKline

      08 GlaxoSmithKline

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20


    • 07 AbbVie

      07 AbbVie

      ...
      Kristin Brooks , Managing Editor, Contract Pharma 07.15.20

    • 06 Sanofi

      06 Sanofi

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 05 Merck

      05 Merck

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    Trending
    • Fujifilm To Invest $2B In US Manufacturing Site
    • Baxter, Novavax Ink Sterile Manufacturing Agreement
    • A New Era Of Vaccine And Biologic Drug Development
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Roche Canada To Invest $500M To Create 500 Jobs In Ontario
    Breaking News
    • KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    • Frontage Bolsters Clinical Services Capabilities
    • Sanofi Unveils EUROAPI as Name of New European API Company
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Precision Medicine Group Acquires Project Farma
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Brown Fat Associated with Reductions in Chronic Disease Risk
    NIH Study Identifies Antibacterial Properties in Taurine
    NSF Begins New Certification Program
    Coatings World

    Latest Breaking News From Coatings World

    Zeppelin Acquires MTI Mischtechnik
    Ezio Braggio Joins ChemQuest Europe
    IFS Coatings Announce Carbon Offset Program
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Optimize EP Launches CaRM Cardiac Device Data Management Platform
    U.S. TAVR Market Projected to Reach Nearly $5 Billion by 2030
    FDA Clears Canon Medical's Compressed SPEEDER for 3D Exams on 1.5T MR
    Contract Pharma

    Latest Breaking News From Contract Pharma

    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    Frontage Bolsters Clinical Services Capabilities
    Sanofi Unveils EUROAPI as Name of New European API Company
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Neenah to Host Packaging Webinar for Printers
    W.S. Badger is Named a ‘150 Top Impact Company’
    Mana Products, Meiyume and RPG Form The Vertical Beauty Alliance
    Happi

    Latest Breaking News From Happi

    A Surge in Interest for Supplements & Vitamins
    P&G, L'Oréal & Amorepacific Make News at CES
    Three Form Vertical Beauty Alliance
    Ink World

    Latest Breaking News From Ink World

    dar-tech, inc. Becomes U.S. Midwestern Distributor for ZS Interpolymer
    Techkon USA, Konica Minolta Partner
    Alon Bar-Shany Appointed Chairman of Highcon Board
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Exhibitor registration opens for virtual.drupa
    FTA planning in-person Forum & INFOFLEX
    Fortis Solutions Group achieves SGP certification
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Shemesh Adds U.S. Headquarters
    TZMO USA, Special Needs Group Form Partnership
    BAHP Announces 2021 Officers, Board of Directors
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Rapid Recovery Protocol Can Lead to Increased Range of Motion After TKA
    Boston Scientific Releases WaveWriter Alpha Spinal Cord Stimulators in U.S.
    New Chief Clinical Officer on Board at IncludeHealth
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Toppan Announces 2050 Environmental Vision
    SOI Industry Consortium Joins SEMI as Strategic Association Partner

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login